These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Study of intermittent endocrine therapy in patients presenting with biologic recurrence after radical prostatectomy or radiotherapy]. de la Taille A; Zerbib M; Conquy S; Amsellem-Ouazana D; Saighi D; Debré B Prog Urol; 2002 Apr; 12(2):240-7. PubMed ID: 12108338 [TBL] [Abstract][Full Text] [Related]
13. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209 [TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Moreau JP; Delavault P; Blumberg J Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109 [TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. Schally AV BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347 [No Abstract] [Full Text] [Related]
16. Long-term follow-up after triple treatment of prostate cancer stage pT3. Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383 [TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue. Smith JA Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267 [No Abstract] [Full Text] [Related]
18. [Hormone treatment of prostate cancer in Norway]. Johansen TE; Berg C Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2558-62. PubMed ID: 19023350 [TBL] [Abstract][Full Text] [Related]
19. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects. Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127 [TBL] [Abstract][Full Text] [Related]
20. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer]. Gez E Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959 [No Abstract] [Full Text] [Related] [Next] [New Search]